Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

A. Viñaras



Author of

  • +

    P1.06 - Poster Session with Presenters Present (ID 458)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P1.06-028 - Description of the Patients with Advanced Squamous NSCLC Treated in a Single Institution (ID 6171)

      14:30 - 14:30  |  Author(s): A. Viñaras

      • Abstract

      Background:
      Squamous carcinomas are a distinct subtype of NSCLC. Even if it is no longer the most frequent one, still remains a significant percentage of NSCLC patients in our practice. Besides, clinical presentation, associated comorbidities and available therapies are different for non-squamous subtypes. Assessing their characteristics may help to optimize therapy.

      Methods:
      DAta from patients with a diagnosis of advanced (stage IV patients plus patients with lower stages but not amenable for any local therapy) squamous NSCLand treated in our Hospital between 2009-15 were reviewed.

      Results:
      209 patients (p) were found. Median age was 69 years (40-89). Gender: Male in 89.5%. PS: ECOG 0= 9.1%, 1= 45.9%, 2= 38.3%, 3= 6.7%. By stage, I= 0.5%, II 3.4%, III 27.7%, IV 68.7%. Therapy: 29.1% of p did not receive any systemic therapy and 70.9% receive chemotherapy (CT). CT included a platinum in 69p (carboplatin 47p, cisplatin 22p) and 61p received a non-platinum scheme (gemcitabine-vinorelbine 21p, monotherapy 40 p (gemcitabine 8p, oral vinorelbine 23p, other 9p). Patients with better PS (p<0.001) and stage less than IV (0.02) were more probable to receive CT and also that CT given included platinum. Overall survival (OS) was 6.5 months (5.4-7.6) for the whole group. For stage IV patients, it was significantly shorter: 5.4 months (p=0.03). OS for patients not receiving therapy was 2.7m (vs 7.7m in those treated). Within stage IV OS was shorter for female vs male (4.2 vs 5.8m), and decreased with poorer performance status: 0, 13.5, 1, 8.2m, 2, 3.8m, 3, 2.2m.

      Conclusion:
      Squamous carcinomas are still the second most frequent subgroup of NSCLC. They are more frequently male and almost half of them presented with PS ≥2. Of them, 29% did not even receive CT and out of those treated, only 60% were considered fit to receive a platinum-based therapy. OS was generally poor, but it was remarkably low in patients with PS 2 or worse. Median OS in untreated patients was under 3 months.